Publications by authors named "Michaela C Barbier"
Background: Malignant pleural mesotheliomas (MPMs) are aggressive and often unresectable. In the past, chemotherapy was the standard for palliative treatment. However, immunotherapy with nivolumab+ipilimumab has recently received marketing approval.
View Article and Find Full Text PDFBackground: In metastatic hormone-sensitive prostate cancer (mHSPC) treatment, survival benefits have been shown by adding docetaxel or recent androgen receptor axis-targeted therapies (ARATs) abiraterone, apalutamide, or enzalutamide to androgen deprivation therapy (ADT). However, the optimal treatment strategy in terms of costs and effects is unclear, not least due to high ARAT costs.
Methods: To assess treatment cost-effectiveness, we developed a Markov cohort model with health states of progression-free disease, progressive disease and death for men with newly diagnosed mHSPC, with a 30-year time horizon.
Context: Multiple treatments for metastatic, hormone-sensitive prostate cancer (mHSPC) are available, but their effects on health-related quality of life (HRQoL) and benefit-harm balance remain unclear.
Objective: To assess clinical effectiveness regarding survival and HRQoL, safety, and benefit-harm balance of mHSPC treatments.
Evidence Acquisition: We searched MEDLINE, EMBASE, CENTRAL, and ClinicalTrials.
Background: The success of colorectal cancer (CRC) screening depends mainly on screening quality, patient adherence to surveillance, and costs. Consequently, it is essential to assess the performance over time.
Methods: In 2000, a closed cohort study on CRC screening in individuals aged 50 to 80 was initiated in Uri, Switzerland.
Article Synopsis
- Pembrolizumab, used alone or with chemotherapy, offers new treatment options for patients with metastatic non-squamous non-small cell lung cancer with high PD-L1 expression in Switzerland.
- A cost-effectiveness analysis showed pembrolizumab monotherapy is likely cost-effective (CHF 68,580/QALY) compared to chemotherapy, while the combination therapy is not (CHF 475,299/QALY).
- The study suggests that, based on willingness-to-pay thresholds, pembrolizumab is a better financial choice for Swiss healthcare payers than the combination therapy.